ЛИ Фан (US),ВАН Хой-Цинь (US),ХЕЛАЙЛОВИК Энсар (US),ЛЯН Цзиншэн (US)
申请号：
RU2016129953
公开号：
RU2016129953A
申请日:
2014.12.19
申请国别(地区):
RU
年份:
2018
代理人:
摘要：
A pharmaceutical combination comprising (a) an ALK inhibitor, or a pharmaceutically acceptable salt thereof, and (b) at least one HDMA-2/p53 receptor inhibitor or a pharmaceutically acceptable salt, or at least one BRaf inhibitor or a pharmaceutically acceptable salt, and optionally a pharmaceutically acceptable carrier, for simultaneous, separate or sequential administration； the uses of such combination in the treatment of cancer； and methods of treating a subject suffering from a proliferative disease comprising administering a therapeutically effective amount of such combination.
